Literature DB >> 19841382

High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study.

M S V Elkind1, J M Luna, Y P Moon, K M Liu, S L Spitalnik, M C Paik, R L Sacco.   

Abstract

OBJECTIVE: To determine whether high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) predict stroke, vascular events, and mortality in a prospective cohort study.
BACKGROUND: Markers of inflammation have been associated with risk of myocardial infarction (MI). Their association with stroke is controversial.
METHODS: The Northern Manhattan Study includes a stroke-free community-based cohort study in participants aged > or =40 years (median follow-up 7.9 years). hsCRP and SAA were measured using nephelometry. Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for the association of markers with risk of ischemic stroke and other outcomes after adjusting for demographics and risk factors.
RESULTS: hsCRP measurements were available in 2,240 participants (mean age 68.9 +/- 10.1 years; 64.2% women; 18.8% white, 23.5% black, and 55.1% Hispanic). The median hsCRP was 2.5 mg/L. Compared with those with hsCRP <1 mg/L, those with hsCRP >3 mg/L were at increased risk of ischemic stroke in a model adjusted for demographics (HR = 1.60, 95% CI 1.06-2.41), but the effect was attenuated after adjusting for other risk factors (adjusted HR = 1.20, 95% CI 0.78-1.86). hsCRP >3 mg/L was associated with risk of MI (adjusted HR = 1.70, 95% CI 1.04-2.77) and death (adjusted HR = 1.55, 95% CI 1.23-1.96). SAA was not associated with stroke risk.
CONCLUSION: In this multiethnic cohort, high-sensitivity C-reactive protein (hsCRP) was not associated with ischemic stroke, but was modestly associated with myocardial infarction and mortality. The value of hsCRP and serum amyloid A may depend on population characteristics such as age and other risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841382      PMCID: PMC2764412          DOI: 10.1212/WNL.0b013e3181bd10bc

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Augmented inverse probability weighted estimator for Cox missing covariate regression.

Authors:  C Y Wang; H Y Chen
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 3.  Coming of age of C-reactive protein: using inflammation markers in cardiology.

Authors:  Edward T H Yeh; James T Willerson
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  C-reactive protein and the future risk of thromboembolic stroke in healthy men.

Authors:  J David Curb; Robert D Abbott; Beatriz L Rodriguez; Pamela Sakkinen; Jordan S Popper; Katsuhiko Yano; Russell P Tracy
Journal:  Circulation       Date:  2003-04-07       Impact factor: 29.690

5.  Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study.

Authors:  S Yamada; T Gotoh; Y Nakashima; K Kayaba; S Ishikawa; N Nago; Y Nakamura; Y Itoh; E Kajii
Journal:  Am J Epidemiol       Date:  2001-06-15       Impact factor: 4.897

6.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

7.  Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.

Authors:  N S Rost; P A Wolf; C S Kase; M Kelly-Hayes; H Silbershatz; J M Massaro; R B D'Agostino; C Franzblau; P W Wilson
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

8.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

9.  Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population.

Authors:  Shinji Makita; Motoyuki Nakamura; Kenyu Satoh; Fumitaka Tanaka; Toshiyuki Onoda; Kazuko Kawamura; Masaki Ohsawa; Kozo Tanno; Kazuyoshi Itai; Kiyomi Sakata; Akira Okayama; Yasuo Terayama; Yuki Yoshida; Akira Ogawa
Journal:  Atherosclerosis       Date:  2008-08-12       Impact factor: 5.162

10.  High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.

Authors:  Mitchell S V Elkind; Vladimir Leon; Yeseon P Moon; Myunghee C Paik; Ralph L Sacco
Journal:  Stroke       Date:  2009-07-30       Impact factor: 7.914

View more
  29 in total

Review 1.  Inflammatory mechanisms of stroke.

Authors:  Mitchell S V Elkind
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

2.  Insulin resistance and systemic inflammation, but not metabolic syndrome phenotype, predict 9 years mortality in older adults.

Authors:  Giovanni Zuliani; Mario Luca Morieri; Stefano Volpato; Marcello Maggio; Antonio Cherubini; Daniela Francesconi; Stefania Bandinelli; Giuseppe Paolisso; Jack M Guralnik; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2014-06-10       Impact factor: 5.162

3.  Molecular mechanisms underlying application of serum procalcitonin and stool miR-637 in prognosis of acute ischemic stroke.

Authors:  You-Mei Li; Xue-Yuan Liu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  C-reactive protein is associated with disability independently of vascular events: the Northern Manhattan Study.

Authors:  Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Joshua Z Willey; Ralph Sacco; Mitchell Sv Elkind
Journal:  Age Ageing       Date:  2017-01-15       Impact factor: 10.668

Review 5.  Role of C-reactive protein when prescribing a statin.

Authors:  Scott Kinlay
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

6.  Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: the Northern Manhattan Study.

Authors:  Jorge M Luna; Yeseon Moon; Khin Liu; Steven Spitalnik; Myunghee Paik; Ralph Sacco; Mitchell S V Elkind
Journal:  Age Ageing       Date:  2013-01-15       Impact factor: 10.668

7.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

8.  Significance of C-reactive protein and transcranial Doppler in cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  Sung-Hwan Hwang; Yong-Sook Park; Jeong-Taik Kwon; Taek-Kyun Nam; Sung-Nam Hwang; Hyun Kang
Journal:  J Korean Neurosurg Soc       Date:  2013-10-31

Review 9.  Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke.

Authors:  Charles C Esenwa; Mitchell S Elkind
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

10.  Periodontal disease and recurrent vascular events in stroke/transient ischemic attack patients.

Authors:  Souvik Sen; Roxanne Sumner; James Hardin; Silvana Barros; Kevin Moss; James Beck; Steven Offenbacher
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-30       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.